Circulating primers enhance platelet function and induce resistance to antiplatelet therapy.

ABSTRACT:

Background

Aspirin and P2Y12 antagonists are antiplatelet compounds that are used clinically in patients with thrombosis. However, some patients are 'resistant' to antiplatelet therapy, which increases their risk of developing acute coronary syndromes. These patients often present with an underlying condition that is associated with altered levels of circulating platelet primers and platelet hyperactivity. Platelet primers cannot stimulate platelet activation, but, in combination with physiologic stimuli, significantly enhance platelet function.

Objectives

To explore the role of platelet primers in resistance to antiplatelet therapy, and to evaluate whether phosphoinositide 3-kinase (PI3K) contributes to this process.

Methods and results

We used platelet aggregation,

SUBMITTER: Blair TA 

PROVIDER: S-EPMC4599128 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature